Silicon BioDevices Inc.
Lab-on-a-chip for rapid heart attack detection
This article was originally published in Start Up
Executive Summary
Silicon BioDevices Inc. is looking to save critical time in heart attack diagnosis as well as billions of dollars in health care costs with the first lab-quality, reader-free, POC device for high-sensitivity measurement of cardiac troponin, a key marker of cardiac damage. Using one drop of whole blood, the company's self-contained blood test provides results within 15 minutes to determine whether or not a patient has experienced a heart attack.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.